MWG Caph Ltd
CIK
2111120
Location
WASHINGTON, DC
Portfolio Value
Micro
$72,368,188
Diversification
Highly concentrated
Filing Date
Dec 31, 2025
Global Rank
#6,227
/ 8,420
Top Industry
Biotechnology
100.0%
3Y Alpha vs SPY
-79.5%
Period ended 6 months ago
Filed Feb 17, 2026 · 4mo
Clone Performance
Feb 2026–Jun 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
-19.9%
SPY
+9.1%
Annualised alpha
-79.5%
Max drawdown
−25.9%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
3 positions · as of Dec 31, 2025Top Position
48.5%
of portfolio value
Top 5
100.0%
of portfolio value
Top 10
100.0%
of portfolio value
HHI
4,267
Highly concentrated
Sector Breakdown
As of Dec 31, 2025| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $72,368,188 |
3 positions ·
$72,368,188 total
· as of Dec 31, 2025
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| BEAM |
Beam Therapeutics Inc.
Healthcare
|
First | 1,266,934 | $35,119,410 | 48.53% | |
| LYEL |
Lyell Immunopharma, Inc.
Healthcare
|
First | 1,008,116 | $31,029,810 | 42.88% | |
| PRME |
Prime Medicine, Inc.
Healthcare
|
First | 1,792,210 | $6,218,968 | 8.59% |